Axa S.A. Buys 9,664 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Axa S.A. increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 6.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,264 shares of the company’s stock after buying an additional 9,664 shares during the period. Axa S.A. owned 0.20% of Pediatrix Medical Group worth $1,248,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Rubric Capital Management LP boosted its holdings in shares of Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after buying an additional 7,241,400 shares in the last quarter. Invenomic Capital Management LP grew its holdings in Pediatrix Medical Group by 93.3% in the fourth quarter. Invenomic Capital Management LP now owns 1,377,951 shares of the company’s stock worth $12,815,000 after purchasing an additional 664,955 shares during the period. Boston Partners increased its stake in shares of Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after purchasing an additional 453,254 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after purchasing an additional 251,072 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth approximately $1,721,000. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares in the company, valued at $343,783.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the transaction, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,100 shares of company stock worth $701,889. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

MD has been the subject of a number of analyst reports. UBS Group lifted their price objective on Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a research note on Friday, August 9th. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Jefferies Financial Group raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and raised their price target for the company from $8.00 to $14.00 in a report on Thursday, September 26th. Truist Financial boosted their price objective on shares of Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 target price on the stock in a report on Friday, June 7th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.30.

Pediatrix Medical Group Price Performance

Shares of NYSE:MD opened at $12.00 on Wednesday. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $1.01 billion, a PE ratio of -14.12, a price-to-earnings-growth ratio of 1.64 and a beta of 1.56. The firm’s 50 day moving average price is $10.12 and its 200-day moving average price is $8.90. Pediatrix Medical Group, Inc. has a twelve month low of $6.62 and a twelve month high of $13.01.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The business had revenue of $504.30 million for the quarter, compared to the consensus estimate of $505.49 million. During the same period last year, the firm earned $0.37 earnings per share. The company’s quarterly revenue was up .7% on a year-over-year basis. Equities research analysts expect that Pediatrix Medical Group, Inc. will post 1.19 EPS for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.